Figure 3

![Figure 3: Summary of pharmacological treatment options for female-pattern hair loss, including FDA-approved and off-label therapies. The therapeutic update reviews evidence for minoxidil, anti-androgens, and newer modalities.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334345/bin/gr3.jpg)

> Source: Paulo Müller Ramos et al. "Female-pattern hair loss: therapeutic update.." *Anais brasileiros de dermatologia*, 2023. PMID: [37003900](https://pubmed.ncbi.nlm.nih.gov/37003900/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334345/bin/gr3.jpg" alt="Summary of pharmacological treatment options for female-pattern hair loss, including FDA-approved and off-label therapies. The therapeutic update reviews evidence for minoxidil, anti-androgens, and newer modalities." />
  <figcaption>Figure 3. Summary of pharmacological treatment options for female-pattern hair loss, including FDA-approved and off-label therapies. The therapeutic update reviews evidence for minoxidil, anti-androgens, and newer modalities.<br>  Source: Paulo Müller Ramos et al. "Female-pattern hair loss: therapeutic update.." <em>Anais brasileiros de dermatologia</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37003900/">37003900</a></figcaption>
</figure>